Compare EAT & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EAT | ALKS |
|---|---|---|
| Founded | 1975 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.8B |
| IPO Year | N/A | 1991 |
| Metric | EAT | ALKS |
|---|---|---|
| Price | $153.75 | $29.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $163.06 | $42.85 |
| AVG Volume (30 Days) | 1.9M | ★ 2.9M |
| Earning Date | 10-29-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.76 | 2.44 |
| EPS | ★ 9.64 | 2.02 |
| Revenue | ★ $5,594,400,000.00 | $1,521,338,000.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $5.09 | $24.60 |
| P/E Ratio | $15.95 | ★ $14.70 |
| Revenue Growth | ★ 23.18 | 1.08 |
| 52 Week Low | $100.30 | $25.17 |
| 52 Week High | $192.22 | $36.45 |
| Indicator | EAT | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 77.11 | 46.66 |
| Support Level | $100.30 | $27.90 |
| Resistance Level | $124.61 | $31.74 |
| Average True Range (ATR) | 6.20 | 1.36 |
| MACD | 5.27 | -0.15 |
| Stochastic Oscillator | 98.38 | 27.71 |
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.